65 related articles for article (PubMed ID: 18507025)
1. Inhibition of PKCalpha activation in human bone and soft tissue sarcoma cells by the selective PKC inhibitor PKC412.
Kawamoto T; Akisue T; Kishimoto K; Hara H; Imabori M; Fujimoto T; Kurosaka M; Hitora T; Kawaguchi Y; Yamamoto T
Anticancer Res; 2008; 28(2A):825-32. PubMed ID: 18507025
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines.
Kawamoto T; Akisue T; Marui T; Nakatani T; Hitora T; Fujita I; Kurosaka M; Yamamoto T
Anticancer Res; 2004; 24(5A):2675-9. PubMed ID: 15517872
[TBL] [Abstract][Full Text] [Related]
3. PKC412--a protein kinase inhibitor with a broad therapeutic potential.
Fabbro D; Ruetz S; Bodis S; Pruschy M; Csermak K; Man A; Campochiaro P; Wood J; O'Reilly T; Meyer T
Anticancer Drug Des; 2000 Feb; 15(1):17-28. PubMed ID: 10888033
[TBL] [Abstract][Full Text] [Related]
4. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
[TBL] [Abstract][Full Text] [Related]
5. The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.
Tenzer A; Zingg D; Rocha S; Hemmings B; Fabbro D; Glanzmann C; Schubiger PA; Bodis S; Pruschy M
Cancer Res; 2001 Nov; 61(22):8203-10. PubMed ID: 11719451
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
7. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.
Li JP; Huang ZJ; Lu XS; Zhou YC; Shao Y; He XP; Chen SR; Wang DD; Qin LS; Sun WH
Oncotarget; 2016 Nov; 7(47):77815-77824. PubMed ID: 27780925
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
10. PKC412 induces apoptosis through a caspase-dependent mechanism in human keloid-derived fibroblasts.
Nakazono-Kusaba A; Takahashi-Yanaga F; Miwa Y; Morimoto S; Furue M; Sasaguri T
Eur J Pharmacol; 2004 Aug; 497(2):155-60. PubMed ID: 15306200
[TBL] [Abstract][Full Text] [Related]
11. Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer.
Kim M; Park IY; Lim J; Kim Y; Han KT; Chung WH; Han K
Ann Clin Lab Sci; 2006; 36(4):455-60. PubMed ID: 17127735
[TBL] [Abstract][Full Text] [Related]
12. PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells.
Sharkey J; Khong T; Spencer A
Blood; 2007 Feb; 109(4):1712-9. PubMed ID: 17032922
[TBL] [Abstract][Full Text] [Related]
13. ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412.
Chi HT; Ly BT; Kano Y; Tojo A; Watanabe T; Sato Y
Biochem Biophys Res Commun; 2012 Dec; 429(1-2):87-92. PubMed ID: 23131561
[TBL] [Abstract][Full Text] [Related]
14. N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells.
Bahlis NJ; Miao Y; Koc ON; Lee K; Boise LH; Gerson SL
Leuk Lymphoma; 2005 Jun; 46(6):899-908. PubMed ID: 16019536
[TBL] [Abstract][Full Text] [Related]
15. Effect of PKC412, a selective inhibitor of protein kinase C, on lung metastasis in mice injected with B16 melanoma cells.
Yoshikawa N; Nakamura K; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
Life Sci; 2003 Feb; 72(12):1377-87. PubMed ID: 12527035
[TBL] [Abstract][Full Text] [Related]
16. The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.
Odgerel T; Kikuchi J; Wada T; Shimizu R; Futaki K; Kano Y; Furukawa Y
Oncogene; 2008 May; 27(22):3102-10. PubMed ID: 18071308
[TBL] [Abstract][Full Text] [Related]
17. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
Zaugg K; Rocha S; Resch H; Hegyi I; Oehler C; Glanzmann C; Fabbro D; Bodis S; Pruschy M
Cancer Res; 2001 Jan; 61(2):732-8. PubMed ID: 11212276
[TBL] [Abstract][Full Text] [Related]
18. CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells.
Luo W; Sharif TR; Houghton PJ; Sharif M
Cell Growth Differ; 1997 Nov; 8(11):1225-40. PubMed ID: 9372245
[TBL] [Abstract][Full Text] [Related]
19. Effect of PKC412, an inhibitor of protein kinase C, on spontaneous metastatic model mice.
Nakamura K; Yoshikawa N; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
Anticancer Res; 2003; 23(2B):1395-9. PubMed ID: 12820400
[TBL] [Abstract][Full Text] [Related]
20. Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production.
Si MS; Reitz BA; Borie DC
Int Immunopharmacol; 2005 Jul; 5(7-8):1141-9. PubMed ID: 15914319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
